Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma

Surgery (United States)

Volumn 158, Issue 4, 2015, Pages 1039-1048

  Zapf, Matthew A C ^a   Kothari, Anai N ^a   Weber, Cynthia E ^a   Arffa, Matthew L ^a   Wai, Phillip Y ^a   Driver, Joseph ^a   Gupta, Gopal N ^a   Kuo, Paul C ^a   Mi, Zhiyong ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DACTINOMYCIN; EPIGALLOCATECHIN GALLATE; MESSENGER RNA; OSTEOPONTIN; RNA; ANTINEOPLASTIC AGENT; CATECHIN; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL MIGRATION; CELL VIABILITY; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CLINICAL EVALUATION; CONCENTRATION PROCESS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HALF LIFE TIME; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MEASUREMENT ACCURACY; MHCC 97H CELL LINE; MTT ASSAY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TEA; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CELL MOTION; DRUG EFFECTS; EVALUATION STUDY; GENETICS; LIVER NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CATECHIN; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; OSTEOPONTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84940793639     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2015.06.011     Document Type: Article

References (28)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. S.T. Fan Hepatocellular carcinoma - resection or transplant? Nat Rev Gastroenterol Hepatol 9 2012 732 737
3. P.Y. Wai, and P.C. Kuo Osteopontin: Regulation in tumor metastasis Cancer Metastasis Rev 27 2008 103 118
4. S.D. Bhattacharya, J. Garrison, H. Guo, and et al. Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines Surgery 148 2010 291 297
5. C. Zhou, H.J. Zhou, X.F. Zhang, and et al. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma Ann Surg Oncol 20 2013 929 937
6. H. Huang, X.F. Zhang, H.J. Zhou, and et al. Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection Cancer Sci 101 2010 1314 1319
7. A.A. Ogunleye, F. Xue, and K.B. Michels Green tea consumption and breast cancer risk or recurrence: a meta-analysis Breast Cancer Res Treat 119 2010 477 484
8. T. Nishikawa, T. Nakajima, M. Moriguchi, and et al. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of bcl-2 family proteins J Hepatol 44 2006 1074 1082
9. Y. Shirakami, M. Shimizu, S. Adachi, and et al. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis Cancer Sci 100 2009 1957 1962
10. Y.C. Hsu, and Y.M. Liou The anti-cancer effects of (-)-epigallocatechin-3-gallate on the signaling pathways associated with membrane receptors in MCF-7 cells J Cell Physiol 226 2011 2721 2730
11. Y. Takami, M.B. Russell, C. Gao, and et al. Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells Surgery 142 2007 163 169
12. C.Y. Chen, N. Ezzeddine, and A.B. Shyu Messenger RNA half-life measurements in mammalian cells Methods Enzymol 448 2008 335 337
13. U. Ullmann, J. Haller, J.P. Decourt, and et al. A single ascending dose study of epigallocatechin gallate in healthy volunteers J Int Med Res 31 2003 88 101
14. H.H. Chow, I.A. Hakim, D.R. Vining, and et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals Clin Cancer Res 11 2005 4627 4633
15. S.D. Bhattacharya, Z. Mi, V.M. Kim, H. Guo, L.J. Talbot, and P.C. Kuo Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model Ann Surg 255 2012 319 325
16. S. Emani, J. Zhang, L. Guo, H. Guo, and P.C. Kuo RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer Surgery 143 2008 803 812
17. J. Zhang, H. Guo, Z. Mi, and et al. EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells Exp Cell Res 315 2009 304 312
18. D. Umeda, S. Yano, K. Yamada, and H. Tachibana Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor J Biol Chem 283 2008 3050 3058
19. Y. Fujimura, M. Sumida, K. Sugihara, S. Tsukamoto, K. Yamada, and H. Tachibana Green tea polyphenol EGCG sensing motif on the 67-kDa laminin receptor PLoS One 7 2012 e37942
20. W.P. Tsang, and T.T. Kwok Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells J Nutr Biochem 21 2010 140 146
21. J. Jin, Y. Chang, W. Wei, and et al. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro Acta Pharmacol Sin 33 2012 701 709
22. M.M. Darweish, A. Abbas, M.A. Ebrahim, and M.M. Al-Gayyar Chemopreventive and hepatoprotective effects of epigallocatechin-gallate against hepatocellular carcinoma: Role of heparan sulfate proteoglycans pathway J Pharm Pharmacol 66 2014 1032 1045
23. I.A. Siddiqui, V.M. Adhami, D.J. Bharali, and et al. Introducing nanochemoprevention as a novel approach for cancer control: Proof of principle with green tea polyphenol epigallocatechin-3-gallate Cancer Res 69 2009 1712 1716
24. A. Smith, B. Giunta, P.C. Bickford, M. Fountain, J. Tan, and R.D. Shytle Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of alzheimer's disease Int J Pharm 389 2010 207 212
25. A. Dube, J.A. Nicolazzo, and I. Larson Chitosan nanoparticles enhance the plasma exposure of (-)-epigallocatechin gallate in mice through an enhancement in intestinal stability Eur J Pharm Sci 44 2011 422 426
26. B. Hu, Y. Ting, X. Yang, W. Tang, X. Zeng, and Q. Huang Nanochemoprevention by encapsulation of (-)-epigallocatechin-3-gallate with bioactive peptides/chitosan nanoparticles for enhancement of its bioavailability Chem Commun (Camb) 48 2012 2421 2423
27. V. Sanna, G. Pintus, A.M. Roggio, S. Punzoni, A.M. Posadino, A. Arca, and et al. Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells J Med Chem 54 2011 1321 1332
28. Y. Baba, J.I. Sonoda, S. Hayashi, N. Tosuji, S. Sonoda, K. Makisumi, and et al. Reduction of oxidative stress in liver cancer patients by oral green tea polyphenol tablets during hepatic arterial infusion chemotherapy Exp Ther Med 4 2012 452 458